INS and type 1 diabetes mellitus: In newly diagnosed T1D patients, two 12-week courses of alefacept preserved C-peptide secretion, decreased insulin requirements and hypoglycemic episodes, and resulted in favorable immunologic profiles more than 1 year after treatment ended (53).